Hansen O, Pfeiffer P, Madsen B, Andersen I, Hansen B, Mathiesen B
Department of Oncology, Odense University Hospital, Odense, Denmark.
Acta Oncol. 1996;35(1):57-61. doi: 10.3109/02841869609098480.
In a randomized double-blind cross-over trial, sustained-release metoclopramide (S) plus methylprednisolone (M) was compared with placebo (P) plus methylprednisolone as antiemetic prophylaxis during two cycles of non-cisplatin chemotherapy. S was administered as 60 mg every 12 h commencing on the evening before chemotherapy up to total of 300 mg metoclopramide in 2.5 days. Evaluation of nausea and vomiting was done by self-assessment schemes and visual analog scales. Fifty patients were included and 36 fulfilled both cycles. Mild nausea and vomiting were experienced by 81% and 83% in the S + M and P + M groups, respectively, while 42% and 39% showed complete control of nausea and vomiting during the first day of treatment. Moderate-dose S did not add to the antiemetic efficacy of M in non-cisplatin chemotherapeutic regimens.
在一项随机双盲交叉试验中，将缓释甲氧氯普胺（S）加甲泼尼龙（M）与安慰剂（P）加甲泼尼龙作为非顺铂化疗两个周期中的止吐预防措施进行比较。S的给药方式为每12小时60毫克，从化疗前一晚开始，在2.5天内总计给予300毫克甲氧氯普胺。通过自我评估方案和视觉模拟量表对恶心和呕吐进行评估。纳入了50名患者，其中36名完成了两个周期。S + M组和P + M组分别有81%和83%的患者经历了轻度恶心和呕吐，而在治疗的第一天，分别有42%和39%的患者恶心和呕吐得到完全控制。在非顺铂化疗方案中，中等剂量的S并未增强M的止吐效果。
